

86CANCER

Compiled Financial Information

Year Ended September 30, 2024

86CANCER
Index to Compiled Financial Information
Year Ended September 30, 2024

| | Page |
|---|------|
| COMPILATION ENGAGEMENT REPORT | 1 |
| COMPILED FINANCIAL INFORMATION | |
| Statement of Financial Position | 2 |
| Statement of Revenues and Expenditures | 3 |
| Statement of Changes in Net Debt | 4 |
| Notes to Compiled Financial Information | 5 |



COMPILATION ENGAGEMENT REPORT

To the Management of 86Cancer

On the basis of information provided by management, I have compiled the statement of financial position of 86Cancer as at September 30, 2024, and the statements of revenues and expenditures and changes in net debt for the year then ended, and Note 1, which describes the basis of accounting applied in the preparation of the compiled financial information ("financial information").

Management is responsible for the accompanying financial information, including the accuracy and completeness of the underlying information used to compile it and the selection of the basis of accounting.

I performed this engagement in accordance with Canadian Standard on Related Services (CSRS) 4200, *Compilation Engagements*, which requires me to comply with relevant ethical requirements. My responsibility is to assist management in the preparation of the financial information.

I did not perform an audit engagement or a review engagement, nor was I required to perform procedures to verify the accuracy or completeness of the information provided by management. Accordingly, I do not express an audit opinion or a review conclusion, or provide any form of assurance on the financial information.

Readers are cautioned that the financial information may not be appropriate for their purposes.

Cold Lake, Alberta
March 21, 2025

Benjamin Dyck Professional Corporation
Chartered Professional Accountant

86CANCER
Statement of Financial Position
September 30, 2024

| | 2024 | 2023 |
|-----------------------------------|----------|---------|
| ASSETS | | |
| CURRENT | | |
| Cash | \$ 1,358 | \$ 638 |
| LIABILITIES AND NET ASSETS | | |
| CURRENT | | |
| Accounts payable | \$ 499 | \$ 499 |
| Short term debt | - | 1,777 |
| Due to directors | 3,900 | 3,333 |
| | 4,399 | 5,609 |
| NET ASSETS | (3,040) | (4,971) |
| | \$ 1,359 | \$ 638 |

ON BEHALF OF THE BOARD

_____*Director*

_____*Director*

See notes to financial information

86CANCER
Statement of Revenues and Expenditures
Year Ended September 30, 2024

| | 2024 | 2023 |
|--|-----------------|-----------------|
| REVENUES | | |
| Product | \$ 6,502 | \$ 3,851 |
| Donations | 413 | 799 |
| Event income | <u>11,076</u> | <u>7,728</u> |
| | <u>17,991</u> | <u>12,378</u> |
| COST OF SALES | | |
| Purchases | 1,317 | 1,589 |
| Merchant fees | <u>-</u> | <u>466</u> |
| | <u>1,317</u> | <u>2,055</u> |
| GROSS PROFIT (92.68%; 2023 - 83.40%) | <u>16,674</u> | <u>10,323</u> |
| EXPENSES | | |
| Advertising and promotion | 695 | 547 |
| Business taxes, licences and memberships | 300 | 506 |
| Donations | 12,400 | 9,200 |
| Interest and bank charges | 214 | 372 |
| Professional fees | <u>1,134</u> | <u>608</u> |
| | <u>14,743</u> | <u>11,233</u> |
| EXCESS (DEFICIENCY) OF REVENUES OVER EXPENSES | <u>\$ 1,931</u> | <u>\$ (910)</u> |

86CANCER
Statement of Changes in Net Debt
Year Ended September 30, 2024

| | 2024 | 2023 |
|---|-------------------|-------------------|
| NET DEBT - BEGINNING OF YEAR | \$ (4,971) | \$ (4,061) |
| EXCESS OF REVENUES OVER EXPENSES | 1,931 | (910) |
| NET DEBT - END OF YEAR | \$ (3,040) | \$ (4,971) |

See notes to financial information

86CANCER
Notes to Compiled Financial Information
Year Ended September 30, 2024

1. BASIS OF ACCOUNTING

The basis of accounting applied in the preparation of the statement of financial position of 86Cancer as at September 30, 2024, and the statements of revenues and expenditures and changes in net debt for the year then ended is the historical cost basis and reflects cash transactions with the addition of:

- Accounts payable and accrued liabilities.
-